Effect of Flexible Catheter Materials on Catheter Angle and Blood Vessel Irritation

NCT ID: NCT06927141

Last Updated: 2025-11-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-26
• Study Completion Date: 2025-10-09

Brief Summary

Peripheral intravenous catheters (PIVCs; commonly known as "cannulas") are very small tubes made out of rubber-like materials which are inserted into patients' arms using a needle to allow easy access to veins. They are the most commonly-used medical devices in the world, with almost 10 million placed each year in Australia alone. Approximately 40% (almost 4 million) of these devices stop working (i.e. fail) prior to completion of therapy.

The main goal of this study is to learn if softer, more flexible PIVC tip materials reduce the angle of the catheter tip on the vein surface compared to less flexible materials. Reducing the angle of the tip is believed to reduce rubbing on the inner vein surface and causing irritation, extending the life of the catheter. Other goals of this study are to learn if softer materials affect: volume of oedema (i.e. fluid leakage around the vein); time until catheter failure; clot volume in the vein; changes in vein size in response to catheter insertion; adverse event rates (i.e. changes in rates of specific, reportable symptoms); and determining if certain catheters are better for some people than others. This study is recruiting participants of all genders aged 18 - 75 years old who:

• Are not pregnant
• Have a Body Mass Index (BMI) between 18.5 - 35 kg/m2
• Have a current Australian Medicare card
• Do not have a history of chronic/infectious disease or clotting disorders
• Do not have a history of recreational drug use or alcohol abuse within the past 2 years

Participants will:

• Spend two hours in the clinic for screening blood collection, medical questionnaire and ultrasound imaging of veins
• Have one more flexible catheter and one less flexible catheter placed in opposite arms (i.e. participants will have a total of two catheters placed) which will remain in place either (i) until they fail or (ii) for 72 hours, whichever is earlier
• Spend eight hours per day in the clinic on the day the catheters are placed and the two days following for observation and ultrasound imaging
• Spend four hours in the clinic on the third day following placement of the catheters for observation, ultrasound imaging and catheter removal
• Spend one hour in the clinic 24-96 hours after catheter removal for a follow-up assessment and questionnaire

Conditions

Healthy; Intravenous Catheterization; Oedema; Thrombosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Left More Flexible Right Less Flexible

Participants in this arm will have a more flexible catheter placed in their left arm.

Group Type: EXPERIMENTAL

Bilateral Peripheral Intravenous Catheterisation

Intervention Type: DEVICE

Participants will have peripheral intravenous catheters inserted. Each participant will receive two different catheters (less flexible = 20 gauge ICUMedical SuperCath5 SP120-20-31T; more flexible = 20 gauge Becton Dickinson Insyte Autoguard Blood Control 381034), with the treatment arm (more flexible) being randomly assigned.

Left Less Flexible Right More Flexible

Participants in this arm will have a less flexible catheter placed in their left arm.

Group Type: EXPERIMENTAL

Bilateral Peripheral Intravenous Catheterisation

Intervention Type: DEVICE

Participants will have peripheral intravenous catheters inserted. Each participant will receive two different catheters (less flexible = 20 gauge ICUMedical SuperCath5 SP120-20-31T; more flexible = 20 gauge Becton Dickinson Insyte Autoguard Blood Control 381034), with the treatment arm (more flexible) being randomly assigned.

Interventions

Bilateral Peripheral Intravenous Catheterisation

Participants will have peripheral intravenous catheters inserted. Each participant will receive two different catheters (less flexible = 20 gauge ICUMedical SuperCath5 SP120-20-31T; more flexible = 20 gauge Becton Dickinson Insyte Autoguard Blood Control 381034), with the treatment arm (more flexible) being randomly assigned.

Intervention Type: DEVICE

Other Intervention Names

Cannulation

Eligibility Criteria

Inclusion Criteria

• Adult aged 18-75 years.
• Not pregnant at time of recruitment and within 48 hrs of Day 1 procedures (self-reported)
• Normal haematology results as per reference range determined by the laboratory.
• Normal coagulation results as per reference range determined by the laboratory.
• Target cephalic veins readily cannulatable (i.e., > 2 mm)
• Able and willing to provide verbal and written consent
• Must be an Australian citizen with current Medicare card

Exclusion Criteria

• History of pro coagulative state / condition (e.g., previous deep vein thrombosis)
• Currently on any anti-coagulant or platelet inhibitor medication. Use of NSAIDs and aspirin will be documented however are not exclusionary.
• Haemophilia or any current or history of bleeding disorder or tendency
• Presence or report of current blood borne disease/infection (e.g., hepatitis, HIV, leukemia, lymphoma)
• History of difficult vascular access
• Allergy or sensitivity to chlorhexidine gluconate, isopropyl alcohol, latex, or skin adhesives
• BMI < 18.5 kg/m2 or ≥ 35 kg/m2
• Positive results for the urine drug screen at screening or check-in (including opiates, methadone, cocaine, amphetamines)
• History or presence of alcoholism (self-reported) or drug abuse within the past 2 years
• A current or previous medical, physical, mental / cognitive disorder or anatomical conditions that, in the opinion of the chief or sub-investigator, would place the patient at risk, would make them unable to perform study procedures or has the potential to confound interpretation of the study results. (e.g., musculo-skeletal injury, chronic back pain)
• Employed by Terumo, Becton Dickinson, Teleflex Medical, ICUMedical or BBraun (conflict of interest)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Queensland University of Technology

OTHER

Sponsor Role: collaborator

University of Galway

OTHER

Sponsor Role: collaborator

Poitiers University Hospital

OTHER

Sponsor Role: collaborator

Terumo Corporation

INDUSTRY

Sponsor Role: collaborator

Queensland Health

OTHER_GOV

Sponsor Role: collaborator

Griffith University

OTHER

Sponsor Role: lead

Responsible Party

Andrew Bulmer

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Principal Investigator

Role: PRINCIPAL_INVESTIGATOR

Griffith University

Locations

Griffith University

Southport, Queensland, Australia

Countries

Australia

Other Identifiers

2025/150

Identifier Type: -

Identifier Source: org_study_id